

Macular Degeneration Age-Related Macular Degeneration Geographic Atrophy

A Study Assessing the Safety, Tolerability, and Efficacy of RO7171009 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

Trial Status
Terminated

Trial Runs In
1 Countries

Trial Identifier
NCT03972709 GR40973

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the safety, tolerability, and efficacy of intravitreal injections of galegenimab (FHTR2163) administered every 4 weeks (Q4W) or every 8 weeks (Q8W) for approximately 76 weeks in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) compared with sham control. After completing the study's last visit (Week 76), eligible participants will have the option to enroll in open-label extension study NCT04607148 (GR42558) and receive open-label galegenimab (FHTR2163) injections.

Genentech, Inc.
Sponsor

Phase 2
Phase

NCT03972709 GR40973
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥60 Years

Healthy Volunteers
No